GlassScriptPhysician profile
Robert L Green
NPI 1073803649
$4,430.15
in general payments reported to CMS, 2019-2025
29 companies · $285 in 2025
The $285 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $938 · 2020: $952 · 2021: $499 · 2022: $678 · 2023: $758 · 2024: $320 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,416.14 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $576.93 | 2019-2025 | |
| Abbvie INC. | $395.98 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $368.79 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $348.69 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.11 | 2019-2023 | Jardiance |
| Amgen INC. | $174.37 | 2019-2025 | Repatha, Prolia, Evenity |
| Metuchen Pharmaceuticals | $130.43 | 2020 | |
| Janssen Pharmaceuticals, INC | $130.31 | 2019-2023 | Xarelto |
| Abbott Laboratories | $72.59 | 2020-2024 | Freestyle Libre |
| Glaxosmithkline, LLC. | $67.77 | 2022-2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $66.33 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $60.65 | 2022-2023 | |
| Astellas Pharma US INC | $58.62 | 2019-2023 | Veozah |
| Amarin Pharma, INC. | $47.28 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.36 | 2019-2023 | Xifaxan |
| Radius Health, INC. | $40.73 | 2019 | |
| Dexcom, INC. | $38.62 | 2024 | Dexcom G6 Transmitter |
| Endogastric Solutions, INC | $30.00 | 2024 | Esophyx |
| E.R. Squibb & Sons, L.L.C. | $21.30 | 2022 | |
| Horizon Therapeutics Plc | $20.58 | 2023 | Krystexxa |
| Xeris Pharmaceuticals, INC. | $20.20 | 2024 | Gvoke Hypopen |
| Merck Sharp & Dohme LLC | $19.81 | 2025 | Capvaxive |
| Takeda Pharmaceuticals U.S.A., INC. | $19.03 | 2020 | |
| Sanofi Pasteur INC. | $17.62 | 2023 | |
| Pulmonx Corporation | $16.26 | 2023 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Daiichi Sankyo INC. | $16.04 | 2019 | |
| Allergan, INC. | $13.67 | 2020 | |
| Gilead Sciences, INC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.